Stock Rating Lowered via ValuEngine
Molecular Templates Inc logoValuEngine reduced shares of Molecular Templates (NASDAQ: MTEM) from a hold score to a promote score in a file issued on Thursday, August 1st, ValuEngine reports.
Several different equities analysts additionally currently commented on the stock. BidaskClub downgraded stocks of Molecular Templates from a preserve score to a promote rating in studies observe on Friday, July 26th. UBS Group assumed coverage on shares of Molecular Templates in a study document on Monday, April twenty-ninth. They set a purchase score and a $12.00 charge goal at the inventory. Finally, Zacks Investment Research reduces stocks of Molecular Templates from a purchase rating to a preserve rating in a research report on Wednesday, June 5th. Three funding analysts have rated the stock with a sell rating and seven have given a buy score to the enterprise’s inventory. Molecular Templates presently has a consensus score of Hold and an average rate goal of $13.58.
NASDAQ: MTEM traded up $0.22 for the duration of midday buying and selling on Thursday, hitting $five.00. The business enterprise had a buying and selling quantity of 113,981 shares, in comparison to its average quantity of 100,702. The enterprise has a short ratio of 3.Eleven, a modern-day ratio of 3.11 and a debt-to-equity ratio of zero.15. The corporation has a marketplace capitalization of $193.55 million, a PE ratio of -four.90 and a beta of 2.77. The inventory’s fifty-day transferring average rate is $6.41 and its 2 hundred-day moving common rate is $6.48. Molecular Templates has a 52-week low of $3.19 and a 52-week high of $8.Seventy-seven.
Molecular Templates (NASDAQ: MTEM) closing posted its quarterly income effects on Monday, August 12th. The biotechnology corporation mentioned ($zero.25) income consistent with the share for the area, missing the consensus estimate of ($zero.23) through ($0.02). The enterprise had sales of $5.Forty five million in the course of the sector, compared to the consensus estimate of $6.00 million. Molecular Templates had a terrible return on equity of 27. Seventy-two % and a poor internet margin of 113.Eighty-five %. As a set, research analysts forecast that Molecular Templates will submit -0.Ninety-two earnings in line with a share for the current yr.
Several hedge price range has recently made changes to their positions in MTEM. BlackRock Inc. Grew its role in stocks of Molecular Templates by means of 26.Four% in the course of the fourth region. BlackRock Inc. Now owns 743,893 stocks of the biotechnology company’s stock really worth $three,0.5,000 after acquiring a further 155,240 shares over the last region. Bank of New York Mellon Corp grew its role in Molecular Templates by 37.6% inside the 4th sector. Bank of New York Mellon Corp now owns 36,854 stocks of the biotechnology corporation’s inventory worth $149,000 after shopping for an additional 10,076 shares over the last sector. Northern Trust Corp grew its position in Molecular Templates through 59.2% within the 4th sector. Northern Trust Corp now owns 165,677 stocks of the biotechnology employer’s stock worth $669,000 after shopping for an extra sixty-one,616 stocks over the last region. Geode Capital Management LLC grew its function in Molecular Templates with the aid of 78.1% within the 4th area. Geode Capital Management LLC now owns 134,069 stocks of the biotechnology company’s inventory worth $541,000 after shopping for a further 58,780 stocks over the past zone. Finally, Fosun International Ltd grew its function in Molecular Templates by 39.Three% inside the 1st region. Fosun International Ltd now owns 162,991 stocks of the biotechnology agency’s inventory worth $940,000 after shopping for an additional 45,968 stocks over the last region. Hedge price range and other institutional investors personal 38.29% of the company’s stock.
Molecular Templates, Inc, a clinical-stage oncology business enterprise, focuses on the discovery and development of biologic therapeutics for the treatment of most cancers and different diseases. The business enterprise typically develops a pipeline of engineered toxin our bodies. Its lead drug candidate is MT-3724 this is in Phase II clinical trial for the remedy of relapsed/refractory diffuse big B-cellular lymphoma; and Phase II scientific trial for treating non-Hodgkin’s lymphoma.